4-hydrazino-2-(4-hydroxy-cyclohexylamino)-benzonitrile | 1292848-43-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-hydrazino-2-(4-hydroxy-cyclohexylamino)-benzonitrile
• 英文别名: 4-hydrazinyl-2-[(4-hydroxycyclohexyl)amino]benzonitrile
• CAS: 1292848-43-1
• 化学式: C₁₃H₁₈N₄O
• 分子量: 246.312
• InChiKey: FAAOAJPIVUYTQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  94.1
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-hydrazino-2-(4-hydroxy-cyclohexylamino)-benzonitrile 在 4-二甲氨基吡啶 、 双氧水 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 、 potassium hydroxide 作用下， 以 乙醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 BJ-B11
  参考文献：
  名称：

  Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11

  摘要：

  In this study, a novel Hsp90 inhibitor BJ-B11, was synthesized and evaluated for in vitro antiviral activity against several viruses. Possible anti-HSV-1 mechanisms were also investigated. BJ-B11 displayed no antiviral activity against coxsackievirus B-3 (CVB3), human respiratory syncytial virus (RSV) and influenza virus (H1N1), but exhibited potent anti-HSV-1 and HSV-2 activity with EC50 values of 0.42 +/- 0.18 mu M and 0.60 +/- 0.21 mu M, respectively. Additionally, the inhibitory effects of BJ-B11 against HSV-1 were likely to be introduced at early stage of infection. Our results indicate that BJ-B11 with alternative mechanisms of action is potent as an anti-HSV clinical trial candidate. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.098
• 作为产物：
  描述：

  4-fluoro-2-(4-trans-hydroxy-cyclohexylamino)-benzonitrile 在 肼 作用下， 反应 3.0h， 以86%的产率得到4-hydrazino-2-(4-hydroxy-cyclohexylamino)-benzonitrile
  参考文献：
  名称：

  Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11

  摘要：

  In this study, a novel Hsp90 inhibitor BJ-B11, was synthesized and evaluated for in vitro antiviral activity against several viruses. Possible anti-HSV-1 mechanisms were also investigated. BJ-B11 displayed no antiviral activity against coxsackievirus B-3 (CVB3), human respiratory syncytial virus (RSV) and influenza virus (H1N1), but exhibited potent anti-HSV-1 and HSV-2 activity with EC50 values of 0.42 +/- 0.18 mu M and 0.60 +/- 0.21 mu M, respectively. Additionally, the inhibitory effects of BJ-B11 against HSV-1 were likely to be introduced at early stage of infection. Our results indicate that BJ-B11 with alternative mechanisms of action is potent as an anti-HSV clinical trial candidate. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.098

文献信息

• Tetrahydroindole and Tetrahydroindazole Derivatives
  申请人：Huang Kenneth He

  公开号：US20080269193A1

  公开（公告）日：2008-10-30

  The invention provides indole and indazole compounds of Formula (I) or pharmaceutically acceptable salts thereof which are useful for treating and/or preventing diseases and/or disorders ameliorated by the inhibition of Heat-Shock Protein 90. The invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of preparing compounds of Formula (I).

  该发明提供了式（I）的吲哚和吲唑化合物，或其药学上可接受的盐，用于治疗和/或预防通过抑制热休克蛋白90改善的疾病和/或紊乱。该发明还提供了包含式（I）化合物的药物组合物以及制备式（I）化合物的方法。
• Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives
  申请人：Huang He Kenneth

  公开号：US20080070918A1

  公开（公告）日：2008-03-20

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 3 , and R 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明涉及公式I的化合物和药学上可接受的盐，其中A、Q1、Q2、Q3、R3和R4的定义如本文所述。公式I的化合物在治疗与细胞增殖有关的疾病和/或情况，如癌症、炎症、关节炎、血管生成等方面具有用途。本发明还涉及包含本发明化合物的制药组合物以及使用这些化合物治疗上述疾病和情况的方法。
• WO2008/24961
  申请人：——

  公开号：——

  公开（公告）日：——
• TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES
  申请人：Serenex, Inc.

  公开号：EP2146967A2

  公开（公告）日：2010-01-27
• [EN] DIHYDROPYRIDAZINE, TETRAHYDROPYRIDINE, CHROMANONE, AND DIHYDRONAPHTHALENONE DERIVATIVES AS HEAT-SHOCK PROTEIN 90 INHIBITORS<br/>[FR] DÉRIVÉS DE DIHYDROPYRIDAZINE, DE TÉTRAHYDROPYRIDINE, DE CHROMANONE ET DE DIHYDRONAPHTALÉNONE
  申请人：SERENEX INC

  公开号：WO2008024961A1

  公开（公告）日：2008-02-28

  [EN] Disclosed are compounds and pharmaceutically acceptable salts of Formula (I), wherein A, Q₁, Q₂, Q₃, R₃, and R₄ are as defined herein. Compounds of Formula (I) are heat-shock protein 90 (HSP-90) inhibitors, useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
  [FR] La présente invention porte sur des composés et des sels de qualité pharmaceutique de Formule I, A, Q₁, Q₂, Q₃, R₃ et R₄ étant tels que définis dans l'invention. Les composés de Formule I peuvent être employés dans le traitement de maladies et/ou d'états pathologiques liés à la prolifération cellulaire, par exemple le cancer, les inflammations, l'arthrite, l'angiogenèse, ou similaire. La présente invention concerne également des compositions pharmaceutiques comprenant les composés selon l'invention et des méthodes de traitement des états pathologiques susmentionnés par emploi de tels composés.